Stroke is a common and costly condition where an effective early treatment may be expected to affect patients' future quality of life, the cost of acute medical treatment, and the cost of rehabilitation and any supportive care needed for their remaining lifetime. To assist in informing discussions on early adoption of potential treatments, economic analyses should accompany investigations that seek to improve outcomes for stroke patients.
Aims
The primary aim is to assess whether i.v./i.a. rt-PA therapy is cost-effective at 3 months compared with i.v. rt-PA, and provides cost-savings or is cost-neutral by 12 months. Design Cost-effectiveness of the two treatment arms will be measured at months 3, 6, 9, and 12. Cost-effectiveness will be calculated using
TaylorTNDavisPHTornerJCHolmesJMeyerJWJacobsonMF: Lifetime cost of stroke in the United States. Stroke1996; 27:1459–66.
2.
LeibsonCLHuTBrownRDHassSLO'FallonWMWhisnantJP: Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology1996; 46:861–9.
3.
DiringerMNEdwardsDFMattsonDTPredictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke1999; 30:724–8.
4.
FaganSMorgensternLPetittaACost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology1998; 50:883–90.
5.
HackeWDonnanGFieschiCAssociation of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004; 363:768–74.
6.
HollowayRGWitterDMJrLawtonKBLipscombJSamsaG: Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology1996; 46:854–60.
7.
EversSMAmentAJBlaauwG: Economic evaluation in stroke research: a systematic review. Stroke2000; 31:1046–53.
8.
DemaerschalkBMYipTR: Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke2005; 36:2500–2503.
9.
GoldMRSiegelJERussellLBWeinsteinMC: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
10.
LeeJSBaileyMJJeongJMauldinPDWeintraubWS: A study on the cost-effectiveness of coronary revascularization: introducing the simultaneous mimic health status model. Health Econ1997; 6:613–23.
11.
MauldinPDJeongJWeintraubWSBeckerER: A multiple outcome model to assess cost-effectiveness: results from the Emory Angioplasty vs. Surgery Trial (EAST). Biometrical J1999; 41:3–23.
12.
MauldinPDWeintraubWSBeckerER: Predicting hospital costs for first-time coronary artery bypass grafting from pre-operative and postoperative variables. Am J Card1994; 74:772–5.
13.
AshbyJ: The accuracy of cost measure derived from Medicare cost report data. Hosp Cost Manage Acc1992; 3:1–8.
14.
EpsteinAMCosts of medical care and out-of-pocket expenditures for persons with AIDS in the Boston Health Study. Inquiry1995; 32:211–21.
15.
TourangeauRRasinskiKA: Evaluation of Data Collection Frequency and the Use of a Summary in the National Medical Utilization and Expenditure Survey. Medical Care Utilization and Expenditure Survey, Series A. Washington, DC: US Government Printing Office, 1987.
16.
KilleenTKBradyKTGoldPBTysonCSimpsonKN: Comparison of self-report versus agency records of service utilization in a community sample of individuals with alcohol use disorders. Drug Alcohol Depend2004; 73:141–7.
17.
ShapiroMFMortonSCMcCaffreyDFVariations in the care of HIV-infected adults in the United States results from the HIV cost and services utilization study. JAMA1999; 281:2305–15.
18.
PerezGMacArthurRDWalmsleySA randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN102). HIV Clin Trials2004; 5:7–18.
19.
The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy1990; 16:199–208.
20.
DolanPA social tariff for EuroQoL: results from a UK general population survey. Discussion paper 138. In: Center for Health Economics. York, UK: The University of York, 1995.
21.
DolanP: Modeling valuations for EuroQol health states. Med Care1997; 35:1095–108.
22.
SandercockPBergeEDennisMCost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke2004; 35:1490–7.
23.
PorsdalVBoysenG: Costs of health care and social services during the first year after ischemic stroke. Int J Tech Assess Health Care1999; 15:573–84.
24.
LipscombJAncukiewiczMParmigianiGHasselbladVSamsaGMatcharDB: Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decision Making1998; 18:S39–56.
25.
HollowayRGWitterDMLawtonKBLipscombJSamsaG: Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology1996; 46:854–60.
26.
EfronBTibshiraniRJ: An Introduction to Bootstrap. New York: Chapman and Hall, 1993.
27.
ChaudharyMAStearnsSC: Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med1996; 15:1447–58.
28.
LittleRARubinDB: Statistical Analysis with Missing Data. New York: Wylie and Sons, 1987.
